Featured Editorial

  1. AI In Clinical Trials: Real Impact, Real Limits, What's Next 4/2/2026

    Claude’s ClinicalTrials.gov connector changes how sponsors access trial data, but does it change outcomes? A recruitment expert weighs in on impact and what’s still missing.

  2. RWD Helps Researchers Include More Patients In Lymphoma Research 4/2/2026

    Andrew Evens, DO, MBA, explores how outcomes research and collaboration across academic networks, registries, and industry partners are advancing more inclusive, data-informed approaches to lymphoma research.

  3. RWE Is Ready — Decision Making For Pharmaceuticals Isn't 4/1/2026

    Gorana Capkun of Merck, KGaA, Darmstadt, Germany discusses the growing role of real-world evidence in clinical trials, highlighting a gap between regulatory momentum and pharma adoption— and the challenge of turning data into better decisions.

  4. Building A Future-Proof, GxP-Compliant IT Infrastructure 3/31/2026

    Learn how a structured IT evaluation framework can help companies model total compliance costs, request vendor qualification evidence, and embed governance requirements into infrastructure selection.

  5. Unlocking Biopharma Innovation With Real-World Evidence 3/30/2026

    Discover how how federated data networks, platform aggregators, and collaborative partnerships have evolved to meet the data demands of modern product development, regulatory strategy, and commercial success.

  6. AI And Clinical Trial Recruitment: Can It Fix The Funnel? 3/26/2026

    Anthropic’s ClinicalTrials.gov connector gives Claude real-time access to trial data. But can conversational AI actually improve patient recruitment strategy?

  7. Elsa's AI Model Migration: Technical, Compliance, And Regulatory Risks For Sponsors (Part 2) 3/26/2026

    In the second part of their series on Elsa AI model migration, Kimberly Chew, Esq., and Michael Yang, Esq., analyze the risks to compliance and data residency, as well as the integrity of the regulatory record.

  8. From Real-World Data To Real-World Impact: Building The Evidence Capability Pharma Actually Needs 3/25/2026

    Learn how companies that treat RWE as an operational capability will be better positioned to design more efficient trials, accelerate therapy adoption, strengthen payer negotiations, and demonstrate value across the healthcare ecosystem.

  9. A Clinical Machine Learning Operations (MLOps) Maturity Framework For Biopharma 3/24/2026

    Pharma has invested substantially in machine learning applications, but investment in the operational infrastructure — the MLOps layer — has lagged. The time to build that infrastructure is now — not after your next trial fails.

  10. Making AI Work For Clinical Trial Supply 3/20/2026

    AI is accelerating clinical trials, but supply teams risk falling behind. Explore how smarter planning, data, and experimentation turn AI into real operational impact.